CymaBay Therapeutics, Inc.

ACTIVE

7601 Dumbarton Cir, 加利福尼亚州阿拉梅达县, California, United Stateswww.cymabay.comPublic101–250 employeesEstablished: 1991-01-01

Also known as:

CBAY

Part of 吉利德科学

Clinical Trials

37 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1991

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

68.5%

Phase 2

20.4%

Phase 3

9.3%

Trial Status Distribution

Active, not recruiting

66.7%

Completed

25.9%

Not yet recruiting

1.9%

Recruiting

1.9%

Terminated

1.9%

Withdrawn

1.9%

Clinical Trials

Trials sponsored by this organization (54)

A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis

Phase 1

Active, not recruiting

interventional

May 2024339 participants

A study to evaluate the safety and tolerability of seladelpar in subjectswith primary biliary cholangitis

Phase 1

Active, not recruiting

interventional

Jan 2023385 participants

A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA).

Phase 1

Active, not recruiting

Apr 2022180 participants

A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA).

Phase 1

Active, not recruiting

Nov 2021180 participants

A clinical trial to assess the safety and efficacy of seladelpar in patientswith primary biliary cholangitis (PBC) and an inadequate response to orintolerance to ursodeoxycholic acid (UDCA).

Phase 1

Active, not recruiting

Jun 2021265 participants

A study to evaluate the safety and tolerability of seladelpar in subjects with primary biliary cholangitis

Phase 1

Active, not recruiting

Jun 2021500 participants

A clinical trial to assess the safety and efficacy of seladelpar in patients with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA).

Phase 1

Active, not recruiting

May 2021180 participants

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Phase 3

Completed

interventional

Apr 2021193 participants

Page 1 of 7

Approvals

No approval data available

News

No news articles found

Back to Organizations